Kura Oncology (NASDAQ:KURA) Shares Up 4.1% – Time to Buy?

Kura Oncology, Inc. (NASDAQ:KURA)’s share price was up 4.1% during trading on Thursday . The stock traded as high as $7.47 and last traded at $7.57. Approximately 30,728 shares changed hands during trading, a decline of 97% from the average daily volume of 1,051,821 shares. The stock had previously closed at $7.27.

Analysts Set New Price Targets

A number of brokerages have weighed in on KURA. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. UBS Group dropped their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. StockNews.com lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Stock Down 0.1 %

The firm’s 50-day moving average is $7.82 and its two-hundred day moving average is $12.49. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $633.12 million, a P/E ratio of -3.32 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock worth $92,307. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC boosted its holdings in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after buying an additional 583,155 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock valued at $41,973,000 after acquiring an additional 615,211 shares during the period. RA Capital Management L.P. bought a new position in Kura Oncology during the 4th quarter worth approximately $38,769,000. Millennium Management LLC grew its holdings in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the period. Finally, Geode Capital Management LLC increased its stake in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.